This paper appears in the following:
- New Orleans: Out Go Classic γ-Secretase Inhibitors, In Come More Dexterous NSAIDs?
- Déjà Vu? AD Patients Again Look Worse on γ-Secretase Inhibitor
- Washington: γ-secretase Inhibitor Survived Phase 2, Moving to 3
- Sorrento: Scientists Stop Clubbing, Start Tweaking, γ-Secretase
- Avagacestat Demise Has Silver Lining for CSF Biomarkers